Bymetric
UK company intelligence
Company Active LTD

Company profile

UCB Pharma Limited

UK company 00209905, incorporated on 24 November 1925.

Home | UCB UK

UCB Pharma Limited is a UK company with status Active founded in 1925 based in South East England.

Company number
00209905
Incorporated
24 Nov 1925
Companies House status
Active

Company identity

Founded / incorporated
24 November 1925

Company number 00209905

Verify at Companies House
Legal name
UCB PHARMA LIMITED
Company type
Private Limited Company
Region
South East England
Registered address
208 BATH ROAD
SLOUGH
BERKSHIRE
SL1 3WE
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

2 levels 1 ultimate controller
1
Company Active LTD
UCB Pharma Limited
CRN 00209905
2
Direct controller Active LTD
Celltech Group Limited
CRN 02159282
3
Ultimate controller Active LTD
UCB (Investments) Limited
CRN 01106309

Company events

Reference milestones and recent Companies House filing stream events.

5 events
30 Sep
2027

Accounts due

Accounts Due

Next accounts due date

26 May
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

12 May
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2025

Accounts filed

Accounts

Last accounts made up date

24 Nov
1925

Incorporated

Inception

Company registered at Companies House

Public funding

1 award
First funded
2016
Funded years
2016
Age at first award
90 years

Projects

2016 Feasibility Studies Lead participant

Feasibility study to determine whether a new generation of catalytic antibodies can be made that overcome existing limitations and are suitable for use in a range of clinical settings

1 Jul 2016 to 30 Jun 2017

Awarded
£60,000
Total cost £120,000

Antibodies, produced naturally in our bodies, have been successfully harnessed by the Biopharma industry to provide a whole new range of safe and effective treatments for unmet patient need. A good example is the anti-TNF antibodies, which are now in common use for suffers of rheumatoid arthritis. Most therapeutic antibodies work by binding to a protein r...

Product types

Feasibility Studies